DCX and neoplasm: Again using a subcutaneous EL4 model, A2aR-null mice exhibited longer tumor-free survival (TFS) and overall survival (OS) when treated with a soluble B7-DC/Fc fusion protein starting on the first day of tumor inoculation and continued for the length of the experiment.